Travere Other Non Cash Items vs Begin Period Cash Flow Analysis

TVTX Stock  USD 17.91  0.77  4.12%   
Travere Therapeutics financial indicator trend analysis is much more than just breaking down Travere Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Travere Therapeutics is a good investment. Please check the relationship between Travere Therapeutics Other Non Cash Items and its Begin Period Cash Flow accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Travere Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.

Other Non Cash Items vs Begin Period Cash Flow

Other Non Cash Items vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Travere Therapeutics Other Non Cash Items account and Begin Period Cash Flow. At this time, the significance of the direction appears to have very week relationship.
The correlation between Travere Therapeutics' Other Non Cash Items and Begin Period Cash Flow is 0.21. Overlapping area represents the amount of variation of Other Non Cash Items that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Travere Therapeutics, assuming nothing else is changed. The correlation between historical values of Travere Therapeutics' Other Non Cash Items and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Non Cash Items of Travere Therapeutics are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Other Non Cash Items i.e., Travere Therapeutics' Other Non Cash Items and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.21
Relationship DirectionPositive 
Relationship StrengthVery Weak

Other Non Cash Items

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.
Most indicators from Travere Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Travere Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Travere Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.At this time, Travere Therapeutics' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 234.2 K in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 113.4 M in 2024.
 2021 2022 2023 2024 (projected)
Research Development210.3M235.8M245.0M123.1M
Depreciation And Amortization26.6M20.7M38.5M19.6M

Travere Therapeutics fundamental ratios Correlations

0.720.840.870.80.54-0.680.60.830.980.920.470.850.820.850.990.20.940.620.20.930.310.680.860.960.6
0.720.680.780.270.96-0.970.810.520.780.790.480.970.950.970.76-0.050.770.87-0.270.580.650.840.460.840.89
0.840.680.870.560.58-0.730.660.570.80.880.450.770.790.790.840.140.940.660.090.790.560.80.680.820.65
0.870.780.870.50.67-0.760.670.630.850.930.430.820.80.860.860.40.950.660.170.80.40.710.710.860.66
0.80.270.560.50.06-0.220.340.750.720.570.250.450.480.460.750.280.630.210.490.850.030.40.850.670.2
0.540.960.580.670.06-0.940.790.260.60.650.430.880.860.880.59-0.10.630.78-0.370.40.710.840.280.710.83
-0.68-0.97-0.73-0.76-0.22-0.94-0.83-0.5-0.74-0.8-0.49-0.93-0.96-0.94-0.730.12-0.78-0.920.33-0.51-0.74-0.86-0.38-0.8-0.95
0.60.810.660.670.340.79-0.830.380.630.650.380.770.860.810.620.00.660.66-0.190.510.740.860.430.710.74
0.830.520.570.630.750.26-0.50.380.840.760.340.660.650.650.820.140.740.590.20.760.080.340.730.740.53
0.980.780.80.850.720.6-0.740.630.840.930.50.880.850.871.00.070.920.70.060.840.330.660.750.980.68
0.920.790.880.930.570.65-0.80.650.760.930.460.870.850.880.930.180.960.740.030.80.450.690.720.920.72
0.470.480.450.430.250.43-0.490.380.340.50.460.50.50.480.5-0.070.440.49-0.150.340.320.440.260.520.49
0.850.970.770.820.450.88-0.930.770.660.880.870.50.960.990.87-0.010.860.84-0.150.730.570.830.630.920.84
0.820.950.790.80.480.86-0.960.860.650.850.850.50.960.970.84-0.030.850.88-0.150.70.690.90.580.890.91
0.850.970.790.860.460.88-0.940.810.650.870.880.480.990.970.870.080.880.84-0.090.760.580.860.660.910.85
0.990.760.840.860.750.59-0.730.620.821.00.930.50.870.840.870.10.930.680.10.870.350.690.780.980.66
0.2-0.050.140.40.28-0.10.120.00.140.070.18-0.07-0.01-0.030.080.10.22-0.140.740.42-0.30.040.50.04-0.14
0.940.770.940.950.630.63-0.780.660.740.920.960.440.860.850.880.930.220.720.140.860.450.750.760.920.7
0.620.870.660.660.210.78-0.920.660.590.70.740.490.840.880.840.68-0.140.72-0.270.440.60.730.310.720.99
0.2-0.270.090.170.49-0.370.33-0.190.20.060.03-0.15-0.15-0.15-0.090.10.740.14-0.270.41-0.54-0.030.50.01-0.28
0.930.580.790.80.850.4-0.510.510.760.840.80.340.730.70.760.870.420.860.440.410.210.630.980.820.42
0.310.650.560.40.030.71-0.740.740.080.330.450.320.570.690.580.35-0.30.450.6-0.540.210.730.080.430.67
0.680.840.80.710.40.84-0.860.860.340.660.690.440.830.90.860.690.040.750.73-0.030.630.730.520.760.79
0.860.460.680.710.850.28-0.380.430.730.750.720.260.630.580.660.780.50.760.310.50.980.080.520.720.29
0.960.840.820.860.670.71-0.80.710.740.980.920.520.920.890.910.980.040.920.720.010.820.430.760.720.72
0.60.890.650.660.20.83-0.950.740.530.680.720.490.840.910.850.66-0.140.70.99-0.280.420.670.790.290.72
Click cells to compare fundamentals

Travere Therapeutics Account Relationship Matchups

Travere Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets604.8M607.4M776.6M672.6M788.9M461.7M
Short Long Term Debt Total204.9M215.7M262.0M407.5M404.8M425.0M
Other Current Liab68.8M80.5M84.9M104.0M119.3M60.3M
Total Current Liabilities95.4M92.7M124.1M142.2M177.9M89.6M
Total Stockholder Equity221.2M211.2M302.1M42.9M200.8M168.0M
Net Debt142.4M130.6M96.2M345.8M346.6M363.9M
Retained Earnings(416.4M)(585.9M)(766.0M)(1.0B)(1.1B)(1.1B)
Accounts Payable26.6M12.1M15.1M17.3M41.7M43.8M
Cash62.4M84.8M165.8M61.7M58.2M58.0M
Cash And Short Term Investments398.5M361.6M552.9M450.2M566.9M284.6M
Common Stock Shares Outstanding42.3M47.5M59.8M63.8M74.3M45.7M
Liabilities And Stockholders Equity604.8M607.4M776.6M672.6M788.9M461.7M
Non Current Liabilities Total288.2M303.6M350.4M487.6M410.2M430.7M
Other Stockholder Equity636.9M798.0M1.1B1.1B1.3B1.4B
Total Liab383.6M396.2M474.5M629.7M588.1M617.5M
Total Current Assets429.1M410.4M582.8M486.4M616.8M316.3M
Short Term Debt2.6M357K7.8M8.9M9.8M9.4M
Property Plant And Equipment Net2.9M9.4M34.3M30.0M25.5M26.8M
Current Deferred Revenue(2.6M)(357K)16.3M12.0M7.1M11.3M
Non Current Assets Total175.7M197.0M193.8M186.1M172.1M169.6M
Non Currrent Assets Other14.7M33.5M11.1M11.1M42.2M44.3M
Other Current Assets6.4M8.1M6.7M15.0M19.3M20.3M
Intangible Assets157.2M153.2M148.4M145.0M103.7M140.4M
Short Term Investments336.1M276.8M387.1M388.6M508.7M288.4M
Property Plant And Equipment Gross2.9M9.4M34.3M30.0M33.0M34.6M
Accumulated Other Comprehensive Income726K(902K)(562K)(2.9M)(1.5M)(1.4M)
Net Receivables18.0M33.1M15.9M16.6M21.2M21.3M
Inventory6.1M7.6M7.3M6.9M9.4M6.0M
Other Liab83.3M59.9M92.4M84.5M76.1M67.7M
Net Tangible Assets63.1M57.1M153.7M(102.2M)(92.0M)(87.4M)
Other Assets14.7M7.8M11.1M36K32.4K30.8K
Long Term Debt204.9M215.3M226.6M375.5M377.3M257.7M
Net Invested Capital426.1M426.6M528.7M418.4M578.1M511.0M
Non Current Liabilities Other83.3M88.2M20.4M73.6M8.5M8.1M
Net Working Capital333.6M317.7M458.7M344.3M438.9M396.7M
Property Plant Equipment2.9M35.1M11.1M9.0M10.4M11.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Travere Stock Analysis

When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.